Matt Brunner
mattjbrunner
A few thoughts on GRIFFIN study:D-RVD vs RVD for frontline treatment of myeloma. Phase 2, randomized, unblinded, about 100 each arm. Primary outcome was sCR rate, which was significantly improved
Read more